Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Allergic Rhinitis, Allergic Asthma
Phase PHASE1, PHASE2
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the safety and tolerability of intralymphatic immunotherapy (ILIT) with ALUTARD SQ Felis domesticus in patients with cat allergy-induced allergic rhinitis and asthma. The main questions it aims to answer are: Is ILIT with ALUTARD SQ Felis domesticus safe and well tolerated? What immunological responses play a role in ILIT? Researchers will compare the effects of ILIT to existing subcutaneous immunotherapy (SCIT) approaches to assess safety, tolerability, immunogenicity, and efficacy. Participants will: Receive 3-4 ILIT injections of ALUTARD SQ Felis domesticus into an inguinal lymph node, guided by ultrasound. Undergo safety monitoring, including WAO guidelines for systemic allergic reactions and tryptase measurement. Complete lung function tests, questionnaires, and a modified nasal provocation test to evaluate asthma effects and treatment efficacy. Provide blood samples for ImmunoCAP and basophil activation testing using CAST ELISA. Inclusion criteria: Adults aged 18-65 with cat-dander-induced allergic rhinitis and asthma. Exclusion criteria: Hypersensitivity to treatment components, systemic steroid use, uncontrolled asthma (FEV1 \< 70%), recent severe asthma exacerbations, or serious comorbidities. The study aims to generate data to inform future efficacy trials.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ALUTARD SQ® Felis domesticus — The drug is approved for use in Switzerland for subcutaneous injections. I this study, we will test the intralympahtic injection

Primary Outcomes

  • Change of blood tryptase levels at baseline, after first ILIT and in case of systemic allergic reactions (From enrollment to the end of treatment at 8 monts. At Baseline, 2 hours after the first Injection and within 1 hour in case of systemic allergic reactions.)
  • Incidence and severity of adverse events using the WAO rating system 2024 (From enrollment to the end of treatment at 8 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-08-20
Completion: 2028-03-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Zurich
Contact Information
Study Contact:
Pål Johansen, Professor, PhD
+41 44 255 8616
pal.johansen@usz.ch
Carole Guillet, MD
+41 43 253 1063
Carole.Guillet@usz.ch
University Hospital Zurich
Claudia V.L. Lang, MD
University Hospital Zurich
Interventions
  • Drug: ALUTARD SQ® Felis domesticus — The drug is approved for use in Switzerland for subcutaneous injections. I this study, we will test the intralympahtic injection
Study Locations (1 sites)
University Hospital Zurich, Zurich, 8091 Switzerland
Eligibility Criteria
Inclusion Criteria: * Informed consent as documented by signature. * Cat-dander-induced ARC as confirmed by patient history and type-1-sensitization to cat dander in skin and/or serum. Exclusion Criteria: * Hypersensitivity to phenol. * Planned depot steroid injection for treatment of ARC * Patients with uncontrolled asthma or FEV1 \< 70% of the predicted value in adults (after adequate pharmacological therapy). * Patients with a severe asthma exacerbation in the past 3 months. * Irreversible secondary changes in the affected organ (e.g., emphysema, bronchiectasis). * Chronic obstructive or restrictive lung disease. * Patients with active systemic autoimmune diseases and patients with immune deficiencies or immune weaknesses. * Severe chronic inflammatory diseases. * Concomitant infection with fever or other signs/symptoms of an acute or chronic infection at treatment visit. * Chronic obstructive or restrictive lung disease * Patients with malignant tumours that currently have clinical significance. * Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension, and treatment with beta-blockers). * Known cardiovascular disease, i.e., not even NYHA class I. * Use of ACE-blockers. * Recent or on-going hepatic or renal disease. * Severe chronic renal insufficiency (due to aluminium burden). * Alcohol or drug abuse * Women who are pregnant and breast feeding * Women of childbearing age who wish to become pregnant or do not use contraception. * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * Participation in another study with investigational drug within the 30 days preceding and during the present study.
Conditions Asthma
Phase NA
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study was to evaluate the Effects of energy conservation exercises versus circuit training on dyspnea, functional capacity and quality of life in asthmatic patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Energy Conservation Technique — Energy conservation technique is used to focus on reducing physical fatigue and improving daily functioning through pacing, planning, prioritizing, and simplifying tasks. 1\. After breathing exercise as a baseline 2. Dictate some activities like that on first patient use more energy expenditure than less it might be his ADL's
  • Other: Circuit Training — Circuit training is a series of exercises that involve little or no rest between repetitions. it is a resistance training for asthmatic patients at their pace. After warm up patient move to next station which consumed higher H.R After that move to resting period like using or working on low H.R

Primary Outcomes

  • 6MWT (through study completion, approximately 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2026-05
Eligibility
Age: 30 Years – 50 Years
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Riphah International University
Principal Investigators:
  • Qurat ul Ain (PRINCIPAL_INVESTIGATOR) - Riphah International University
Contact Information
Study Contact:
Dr Imran Amjad, PhD
(+92) 03324390125
imran.amjad@riphah.edu.pk
Qurat ul Ain
+92 3207374003
qurat.ain@riphah.edu.pk
Doctor's hospital
Malaika Ashraf, CPPT
Doctor's hospital
Interventions
  • Other: Energy Conservation Technique — Energy conservation technique is used to focus on reducing physical fatigue and improving daily functioning through pacing, planning, prioritizing, and simplifying tasks. 1\. After breathing exercise as a baseline 2. Dictate some activities like that on first patient use more energy expenditure than less it might be his ADL's
  • Other: Circuit Training — Circuit training is a series of exercises that involve little or no rest between repetitions. it is a resistance training for asthmatic patients at their pace. After warm up patient move to next station which consumed higher H.R After that move to resting period like using or working on low H.R
Study Locations (1 sites)
Doctor's hospital, Jhang, Punjab Province 35200 Pakistan
Eligibility Criteria
Inclusion Criteria: \- Subjects with asthma diagnosis grade according to FEV 60%-80% Exclusion Criteria: * Pregnancy * Previous breathing exercise training * Severe comorbidity * Patients with short life expectancy * subjects with Severe physical impairments * Subjects with Mental disease
Conditions Asthma in Children
Phase NA
Enrollment 420
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The overall goal of this research study is to evaluate a multi-level program called PRAGMATIC-S to improve the delivery of guideline-based asthma care through a unique partnership between clinical practices and schools. PRAGMATIC-S represents a novel approach that addresses multiple barriers to adherence by bridging primary care and schools, ensuring delivery of guideline-based asthma care to urban children across these settings thereby improving adherence to therapy and clinical outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: PRAGMATIC-S — Intervention combines EHR-based guideline prompts, electronic MAF submission, school-based directly observed therapy (DOT), and Asthma Outreach Workers (AOWs) providing care coordination, adherence support, and communication between families, schools, and providers.

Primary Outcomes

  • Asthma Control - continuous (Baseline, 4 months, 8 months, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-12
Completion: 2033-06-30
Eligibility
Age: 4 Years – 12 Years
Sex: ALL
Volunteers: false
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Montefiore Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Marina Reznik, MD, MS (PRINCIPAL_INVESTIGATOR) - Montefiore Medical Center
Contact Information
Study Contact:
Marina Reznik, MD, MS
718-741-2494
mreznik@montefiore.org
Marina Reznik, MD, MS
718-741-2494
mreznik@montefiore.org
Children's Hospital at Montefiore, Albert Einstein College of Medicine
Interventions
  • Behavioral: PRAGMATIC-S — Intervention combines EHR-based guideline prompts, electronic MAF submission, school-based directly observed therapy (DOT), and Asthma Outreach Workers (AOWs) providing care coordination, adherence support, and communication between families, schools, and providers.
Study Locations (1 sites)
Children's Hospital at Montefiore, Albert Einstein College of Medicine, The Bronx, New York 10467 United States
Eligibility Criteria
Inclusion Criteria: * Physician-diagnosed asthma documented in EHR * Persistent asthma, not on controller medications or uncontrolled asthma despite therapy (with any one of the following per age-specific guidelines: in past month, \>2 days/week with symptoms, \>2 days/week using rescue medication, \>2 days/month with nighttime symptoms, or \>2 episodes/year that required systemic corticosteroids * Age 4 to 12 years, inclusive, attending pre-kindergarten through 7th grade in public / charter / private schools in New York City (the Bronx primarily) and also schools in lower Hudson Valley (Eastchester, Westchester, Rockland, Yonkers) * Caregiver is able to speak and understand either English or Spanish. Participants unable to read will be eligible as all surveys will be administered verbally by research personnel * Consent from primary caregiver and assent from child (age ≥7 years). If there are eligible siblings with exact same asthma severity/control screening results, one child will be randomly selected to participate, otherwise the sibling with worse asthma symptoms will be selected. * Presence of a phone to conduct surveys and smartphone, iPad or computer to electronically complete and e-sign MAF Exclusion Criteria: * Family plans to leave school or city within 6 months * Significant medical conditions (e.g., congenital heart disease, cystic fibrosis, or other chronic lung disease) * Children in foster care or other situations in which consent cannot be obtained from a legal guardian * Participation in concurrent asthma intervention study * Severe developmental delay (e.g., severe autism) precluding completion of asthma control questionnaire
Conditions Breathing, Lung Function Decreased, Asth...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on methacholine challenge testing and whether these findings are associated with body habitus,

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Oscillometer — The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).

Primary Outcomes

  • Oscillometer (Single measurement, approximately day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-17
Completion: 2027-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Rochester
Contact Information
Study Contact:
Patrick Donohue, MD
(585) 210-9301
patrick_donohue@urmc.rochester.edu
Interventions
  • Device: Oscillometer — The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
Study Locations (1 sites)
University of Rochester Medical Center, Rochester, New York 14620 United States
Eligibility Criteria
Inclusion Criteria: * Willingness to perform breathing test * Must be able to speak and understand English * Referred for Methacholine Challenge Test Exclusion Criteria: * Unable to provide consent or perform oscillometry test
Conditions Moderate to Severe Asthma
Phase PHASE2
Enrollment 195
Locations 44 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study is a phase II study of RC1416 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of RC1416 in subjects with severe uncontrolled asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: RC1416 — There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.
  • Drug: RC1416 Placebo — Each subjects will receive the placebo by subcutaneous injection

Primary Outcomes

  • Pre-bronchodilator (Pre-BD) forced expiratory volume in 1 Second (FEV1) (During 32 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-10
Completion: 2028-02-28
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 195 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanjing RegeneCore Biotech Co., Ltd.
Contact Information
Study Contact:
Guo Qian
+86-025-58608860
guoqian@regenecore.com
0556-5223968
Anqiing Municipal Hospital
Jiang Hui
Wanbei Coal-Electricity Group General Hospital
Interventions
  • Drug: RC1416 — There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.
  • Drug: RC1416 Placebo — Each subjects will receive the placebo by subcutaneous injection
Study Locations (44 sites)
Anqiing Municipal Hospital, Anqing, Anhui 246004 China
Wanbei Coal-Electricity Group General Hospital, Suzhou, Anhui 234000 China
China-Japan Friendship Hospital, Beijing, Beijing Municipality 100029 China
The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality 402160 China
Gansu Provincial People's Hospital, Lanzhou, Gansu 730000 China
The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051 China
The Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000 China
Xingtai People's Hospital, Xingtai, Hebei 054001 China
The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000 China
Daqing Oilfield General Hospital, Daqing, Heilongjiang 163001 China
Eligibility Criteria
Inclusion Criteria: * Male or female aged 18 and 75 years. * Diagnosed with asthma for at least 1 year, and the current disease status meets the diagnostic criteria of the 2024 GINA guidelines. * Have received medium-to-high dose ICS therapy for at least 3 consecutive months prior to screening, and maintained a stable treatment regimen and dose for ≥1 month prior to baseline. * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) measurement ≤80% of the predicted normal value at both the screening and baseline visits. * Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5 at both the screening and baseline visits. * Must have experienced ≥1 severe asthma exacerbation event within the 12 months prior to screening. * Positive bronchodilator reversibility test. Exclusion Criteria: * Individuals with a known history of allergy to the investigational product or its excipients. * Clinically diagnosed with chronic obstructive pulmonary disease (COPD) or other lung diseases that may impair lung function . * Experienced a severe asthma exacerbation event from within 1 month prior to screening until before dosing. * Used systemic corticosteroids within 1 week prior to screening. * Had a pulmonary or other site infection requiring intravenous antibiotics, antifungals, or antivirals from within 1 month prior to screening until before dosing. * Used traditional Chinese medicine with anti-asthmatic effects within 1 month prior to screening. * Underwent major surgery within 8 weeks prior to screening or plans to undergo major surgery during the study period. * With a history of malignancy within the past 5 years . * Active or incompletely treated tuberculosis * Used biologic/systemic immunosuppressant/immunomodulators within 12 weeks or 5 half-lives prior to screening. * Diagnosed active parasitic infection; suspected parasitic infection or high risk of infection. * Abnormal 12-lead electrocardiogram (ECG) at screening. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Conditions Asthma, Chronic Obstructive Pulmonary Di...
Phase Not Applicable
Enrollment 800
Locations 45 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and quality of life. Also, there is scarcity of data regarding the phenotypes of asthmatics who benefit the most from the use of fixed triple combinations.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg — In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.

Primary Outcomes

  • Asthma control Test (6 months)
  • Asthma control Test 2 (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-24
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chiesi Hungary Ltd.
Contact Information
Study Contact:
András Keglevich, Dr.
+36309788085
a.keglevich@chiesi.com
Balázs Sánta, Dr.
+36309948432
b.santa@chiesi.com
Árpád Vincze, Dr.
Békés Megyei Központi Kórház, 2. Tüdőgyógyászat szakrendelés - 1. rendelés
Interventions
  • Drug: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg — In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
Study Locations (45 sites)
Békés Megyei Központi Kórház, 2. Tüdőgyógyászat szakrendelés - 1. rendelés, Békéscsaba, Hungary
Kispesti Egészségügyi Intézet Tüdőgondozó, Ernyőképszűrő állomás, Budapest, Hungary
Országos Korányi Pulmonológiai Intézet (OKPI), Budapest, Hungary
Semmelweis Egyetem, Általános Orvostudományi Kar, Pulmonológiai Klinika, Budapest, Hungary
Szent Kristóf Szakrendelő XI. Kerületi Tüdőgondozó, Budapest, Hungary
Szent Kristóf Szakrendelő XXII. Kerületi Tüdőgondozó, Budapest, Hungary
XVI. Kerület Kertvárosi Egészségügyi Szolgálata, Tüdőgyógyászat, Budapest, Hungary
Csornai Margit Kórház Tüdőbeteggondozó Intézet, Csorna, Hungary
DE Klinikai Központ, Tüdőgyógyászati Klinika, Debrecen, Hungary
Debreceni Egyetem Kenézy Gyula Egyetemi Kórház Pulmonológiai Részleg, Debrecen, Hungary
Eligibility Criteria
INCLUSION CRITERIA: * Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion * Patients ≥ 18 years of age in ambulatory care * Uncontrolled asthma according to the physician's clinical assessment despite the use of 1. LABA - high dose ICS OR 2. LABA - high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months. * Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC and the financing protocol for asthma 1. At least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months 2. Uncontrolled asthma (ACT≤15) 3. FEV1\<80% at baseline * Inhaled asthma therapy was changed to Trimbow 172/5/9 μg pMDI no more than 1 week prior to OR on the day of study inclusion * Patient provided written, informed consent to study participation EXCLUSION CRITERIA: * Participation in any clinical trial within 30 days prior to enrolment * Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment * Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment. * Continuous use of oral (\>5 mg prednisolone/day OR \>4 mg methylprednisolone/day) OR intravenous corticosteroids CHMED\_2024/01 Prof. Dr. Lilla Tamási 8(17) * Use of continuous oxygen therapy * Any malignant disease in the last 5 years * Tuberculosis (active or anamnestic) * Actual or previous use of biologics for asthma treatment in the past 12 months * All exclusion criteria listed in Trimbow 172/5/9 μg pMDI SmPC
Conditions Severe Asthma, COPD, Non-CF Bronchiectas...
Phase Not Applicable
Enrollment 8
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with muco-obstructive pulmonary disease. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Combination Product: Hyperpolarized 129 Xenon — Xenon gas contrast agent for MRI

Primary Outcomes

  • Ventilation Defect in Mucus blocked Regions (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-01
Completion: 2026-12
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 8 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Kansas Medical Center
Collaborators: Polarean Imaging, Plc
Contact Information
Study Contact:
Cristal Monge
(913) 945-9399
chernandez@kumc.edu
Cristal Monge
(913) 945-9399
chernandez@kumc.edu
University of Kansas Medical Center
Peter Niedbalski, PhD
University of Kansas Medical Center
Interventions
  • Combination Product: Hyperpolarized 129 Xenon — Xenon gas contrast agent for MRI
Study Locations (1 sites)
University of Kansas Medical Center, Kansas City, Kansas 66160 United States
Eligibility Criteria
Inclusion Criteria: * Adequate completion of informed consent process with written documentation * Patients 18 - 65 years old * • Physician diagnosis of muco-obstructive pulmonary disease, including cystic fibrosis, severe asthma, chronic obstructive pulmonary disease, or non-cystic fibrosis bronchiectasis for \> 1 year * Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs. Exclusion Criteria: * Respiratory tract infection within the 4 weeks prior to Visit 1 * Body mass index (BMI) \> 30 at Visit 1 * One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1 * ER visit related to pulmonary condition within the previous 4 weeks of Visit 1 * Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.) * Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal canula * Positive urine pregnancy test * Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study * Unable or unlikely to complete study assessments in the opinion of the Investigator * Study intervention poses undue risk to patient in the opinion of the Investigator * Conditions that will prohibit MRI scanning determined by the MRI safety screening.
Conditions Bronchial Asthma, Pulmonary Cystic Fibro...
Phase Not Applicable
Enrollment 450
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Collection of breath condensate — Breath condensate will be collected from the patients involved in study.

Primary Outcomes

  • Biomarker identification using method of High Resolution Mass Spectrometry processed on Orbitrap Velos Elite machine (18 months from the screening)
  • FEV1 determination in Cystic Fibrosis patients (18 months from the screening)
  • FVC determination in Cystic Fibrosis patients (18 months from the screening)
  • Amylase readings in blood serum in Cystic Fibrosis patients (18 months from the screening)
  • Lipase readings in blood serum in Cystic Fibrosis patients (18 months from the screening)
  • Microbiology cultivation in Cystic Fibrosis patients (18 months from the screening)
  • CT in Cystic Fibrosis patients (18 months from the screening)
  • RTG in Cystic Fibrosis patients (18 months from the screening)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2015-05-01
Completion: 2026-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
Collaborators: University Hospital Olomouc
Principal Investigators:
  • Petr Dzubak, MD, PhD. (STUDY_DIRECTOR) - The Institute of Molecular and Translational Medicine, Czech Republic
Contact Information
Study Contact:
Petr Dzubak, MD, PhD.
585632150
petr.dzubak@upol.cz
Marian Hajduch, MD, PhD
585632
marian.hajduch@upol.cz
Petr Dzubak, MD, PhD
+420 585632150
petr.dzubak@upol.cz
University Hospital Olomouc
Interventions
  • Diagnostic Test: Collection of breath condensate — Breath condensate will be collected from the patients involved in study.
Study Locations (1 sites)
University Hospital Olomouc, Olomouc, 77900 Czechia
Eligibility Criteria
Inclusion Criteria: * Children/adults with moderate or IgE mediated asthma * Children/adults with cystic fibrosis * Healthy control children/adults without lung disorders Exclusion Criteria: \-
Conditions Asthma, Inflammation, Asthma in Children
Phase Not Applicable
Enrollment 1500
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this observational study is to assess the relevance of inflammometry (based on the measurement of fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC)) as a tool for prioritizing respiratory diagnostic tests. The study will evaluate the role of inflammometry (FeNO and BEC) in prioritizing diagnostic respiratory tests. It will include patients aged six and older with suspected asthma, referred by non-pulmonologists for diagnostic asthma testing (spirometry or methacholine challenge test) at three hospital centers: Sherbrooke University Hospital Center (CHUS), Sainte-Justine University Hospital Center (CHU Sainte-Justine), and the Montreal Children's Hospital. The hypothesis is that using inflammometry as a prioritization tool would reduce diagnostic delays for high-risk patients with elevated biomarkers. This study could help shorten wait times, relieve congestion in diagnostic testing queues, and improve the diagnostic pathway. Additionally, it would enhance the interpretation of pulmonary function test results by incorporating inflammometry findings, leading to better patient stratification. Patients referred from primary care will undergo pulmonary function testing (spirometry ± methacholine challenge) and, as part of the study: FeNO measurement using a portable device Blood test for eosinophil count Questionnaire on asthma control and quality of life, completed at the visit and at follow-ups at 4, 8, and 12 months

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: FeNO — FeNO measured with a NIOX VERO device before the respiratory test
  • Diagnostic Test: blood sample — Blood sample for measuring the blood eosinophil count

Primary Outcomes

  • Comparison of the diagnostic delay for asthma in patients with high risk due to elevated inflammatory markers versus those with low risk (At the time of the methacholine challenge test)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-24
Completion: 2027-07-01
Eligibility
Age: 6 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Université de Sherbrooke
Collaborators: AstraZeneca, Niox Group Plc, Ministere de la Sante et des Services Sociaux, Association Pulmonaire du Quebec, Fonds recherche du Québec Santé
Contact Information
Study Contact:
Simon Couillard, MD, MSc
+1-819-346-1110
s.couillard@usherbrooke.ca
Garry Cormier, Inh
+15143454931
garry.cormier.hsj@ssss.gouv.qc.ca
CHU Sainte-Justine
Sze Man Tse, MD
CHU Sainte-Justine
Interventions
  • Diagnostic Test: FeNO — FeNO measured with a NIOX VERO device before the respiratory test
  • Diagnostic Test: blood sample — Blood sample for measuring the blood eosinophil count
Study Locations (3 sites)
CHU Sainte-Justine, Montreal, Quebec H3T 1C5 Canada
Montreal Children's Hospital, Montreal, Quebec H4A 3H9 Canada
CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec J1H 5N4 Canada
Eligibility Criteria
Inclusion Criteria: * patients age 6 and older * referred by primary care ofr an asthma diagnostic test (spirometry or methacholine challenge) Exclusion Criteria: * referred by pulmonologist
Conditions Asthma, Asthma Attack, Asthma in Childre...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation. Methodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited. Importance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation. Potential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Device: AeviceMD device — The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
  • Behavioral: Standard care — All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.

Primary Outcomes

  • Rescue therapy (up to 12 weeks)
  • Dose of oral Prednisolone use (up to 12 weeks)
  • Visit to hospital emergency department (up to 12 weeks)
  • Hospitalisation (up to 12 weeks)
  • Euro Quality of Life 5 dimensions (EQ5D) (up to 12 weeks (baseline, week 4, week, 12))
  • Asthma quality of life questionnaire (AQLQ) (up to 12 weeks (baseline, week 4, week, 12))
  • Pediatric asthma quality of life questionnaire (PAQLQ) (up to 12 weeks (baseline, week 4, week, 12))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-01
Completion: 2025-12-30
Eligibility
Age: 7 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SingHealth Polyclinics
Principal Investigators:
  • Mabel QH Leow, PhD (PRINCIPAL_INVESTIGATOR) - SingHealth Polyclinics
Contact Information
Study Contact:
Mabel QH Leow, PhD
+65 63507598
mabel.leow.q.h@singhealth.com.sg
Mabel QH Leow, MD, PhD
+65 6350-7598
mabel.leow.q.h@singhealth.com.sg
SingHealth Polyclinics
Interventions
  • Device: AeviceMD device — The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
  • Behavioral: Standard care — All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
Study Locations (1 sites)
SingHealth Polyclinics, Singapore, 150167 Singapore
Eligibility Criteria
Inclusion Criteria: * Diagnosis of asthma * Pediatric patients (age 7 to 17), adult patients (age 18 and above * Have an asthma exacerbation on the day of visit * Be willing to use the AeviceMD device * Has a smart phone to download the application that is paired with Aevice * Has wireless fidelity (WIFI) connection to use with Aevice * English speaking Exclusion Criteria: * No capacity for consent * Concurrent chronic obstructive pulmonary disease (COPD)
Conditions Asthma, COPD, Interstitial Lung Disease,...
Phase PHASE1
Enrollment 260
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Hyperpolarized Xe129 — During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.

Primary Outcomes

  • RBC/Barrier Ratio (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2020-11-02
Completion: 2028-10-26
Eligibility
Age: 3 Years and older
Sex: ALL
Volunteers: true
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mario Castro, MD, MPH
Principal Investigators:
  • Peter Niedbalski, PHD (PRINCIPAL_INVESTIGATOR) - University of Kansas Medical Center
Contact Information
Study Contact:
Cristal Monge
913-945-9399
chernandez@kumc.edu
Peter J Niedbalski, PhD
9135882271
pniedbalski@kumc.edu
University of Kansas Medical Center
Interventions
  • Drug: Hyperpolarized Xe129 — During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
Study Locations (1 sites)
University of Kansas Medical Center, Kansas City, Kansas 66160 United States
Eligibility Criteria
Inclusion Criteria: Healthy Volunteers: * Subject has no diagnosed pulmonary conditions * Ability to read and understand English or Spanish Subjects with Lung Disease: * Subject has a diagnosis of pulmonary dysfunction made by a physician * No acute worsening of pulmonary function in the past 30 days * Ability to read and understand English or Spanish Exclusion Criteria: * MRI is contraindicated based on responses to MRI screening questionnaire * Subject is pregnant or lactating * Subject does not fit into 129Xe vest coil used for MRI * Subject cannot hold his/her breath for 15-16 seconds * Subject deemed unlikely to be able to comply with instructions during imaging * Oxygen saturation \<88% on room air or with supplemental oxygen * Cognitive deficits that preclude ability to provide consent * Institutionalization
Conditions Asthma
Phase NA
Enrollment 56
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

To compare the effects of aerobic training and behavioural intervention to increase physical activity in the clinical control of asthma and in the quality of life of patients with asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Behavioral Intervention to Increase Physical Activity — The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
  • Other: Aerobic Training — The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.

Primary Outcomes

  • Change in asthma clinical control ([Change from baseline at 8 weeks of intervention and at 16 weeks post intervention])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-23
Completion: 2025-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Collaborators: Fundação de Amparo à Pesquisa do Estado de São Paulo
Principal Investigators:
  • Celso RF Carvalho, PhD (STUDY_DIRECTOR) - University of Sao Paulo General Hospital
Contact Information
Study Contact:
Celso RF Carvalho, PhD
55 11 98415-3234
cscarval@usp.br
Celso RF Carvalho, PhD
cscarval@usp.br
Clinical Hospital of São Paulo University medical school (HCFMUSP)
Interventions
  • Behavioral: Behavioral Intervention to Increase Physical Activity — The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
  • Other: Aerobic Training — The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.
Study Locations (1 sites)
Clinical Hospital of São Paulo University medical school (HCFMUSP), São Paulo, São Paulo 05360-160 Brazil
Eligibility Criteria
Inclusion Criteria: 1. Participants not physically active; 2. Uncontrolled asthma (ACQ\>1,5); 3. Diagnosis of asthma based on the recommendations of the Global Initiative for Asthma (GINA 2020); 4. Be under outpatient follow-up at the Pulmonology or Immunology service of the University of Sao Paulo General Hospital; 5. Be under outpatient medical treatment for at least six months, with a stable clinical condition for at least 30 days; 6. Being using optimized drug therapy for asthma. Exclusion Criteria: 1. Participation in another research protocol; 2. Difficulty in understanding any of the questionnaires used; 3. Practitioners of regular physical activity; 4. Pregnancy and psychiatric problems that make it difficult to understand the questionnaires and the study protocol; 5. Presence of another chronic lung, neurological or musculoskeletal disease that hinders or prevents physical activity; 6. Patients who are smokers or ex-smokers (who have quit smoking for less than 1 year or who have smoked more than 15 pack-years).